Secondary Primary Malignancies Rare After CAR T-Cell Immunotherapy

FRIDAY, Feb. 2, 2024 -- The incidence of secondary primary malignancy after anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy is very low, according to a study published online Jan. 24 in Nature Medicine.Guido Ghilardi, Ph.D., from the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news